A Study of ZN-c3 in Patients With Ovarian Cancer
Recruiting
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Site 0259, Durham, North Carolina
Conditions: Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer